Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27637374 | 0.94 | TSHR (0.53) | TSHRALDH1A1PPARGCYP3A4MAPK1 | |
| SCHEMBL16673220 | 0.90 | LMNA (0.50) | TSHRTDP1L3MBTL1ALDH1A1PPARG | |
| SCHEMBL28003097 | 0.88 | PPARG (0.51) | TSHRTDP1L3MBTL1ALDH1A1PPARG | |
| SCHEMBL28825718 | 0.85 | PPARG (0.43) | PPARGPPARASMN1; SMN2FAAH | |
| SCHEMBL7248945 | 0.85 | PPARG (0.51) | TSHRTDP1L3MBTL1ALDH1A1PPARG | |
| SCHEMBL13444679 | 0.84 | TSHR (0.51) | TSHRALDH1A1PPARGCYP3A4MAPK1 | |
| SCHEMBL13763449 | 0.84 | TSHR (0.44) | TSHRALDH1A1PPARACYP3A4MAPK1 | |
| SCHEMBL767041 | 0.83 | TDP1 (0.55) | TSHRTDP1L3MBTL1ALDH1A1PPARG | |
| SCHEMBL16672556 | 0.83 | L3MBTL1 (0.57) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL13864205 | 0.82 | TLR4 (0.42) | TSHRTDP1L3MBTL1ALDH1A1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2869389-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | MITSUBISHI CHEM CORP (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-10320030-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20150140448-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2869389-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | Mitsubishi Chemical Corporation (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107135-A1 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 | PLA2G1B, PLA2G4A, PLA2G4B | TSHR 3285/4885TDP1 784/4885L3MBTL1 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.